601 related articles for article (PubMed ID: 27692977)
21. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
22. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Ryan G; Jahnke N; Remmington T
Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
[TBL] [Abstract][Full Text] [Related]
23. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
McKeage K
Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436
[TBL] [Abstract][Full Text] [Related]
24. Testing the effects of combining azithromycin with inhaled tobramycin for
Nichols DP; Singh PK; Baines A; Caverly LJ; Chmiel JF; GIbson RL; Lascano J; Morgan SJ; Retsch-Bogart G; Saiman L; Sadeghi H; Billings JL; Heltshe SL; Kirby S; Kong A; Nick JA; Mayer-Hamblett N;
Thorax; 2022 Jun; 77(6):581-588. PubMed ID: 34706982
[TBL] [Abstract][Full Text] [Related]
25. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
[TBL] [Abstract][Full Text] [Related]
26. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
27. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
Nick JA; Moskowitz SM; Chmiel JF; Forssén AV; Kim SH; Saavedra MT; Saiman L; Taylor-Cousar JL; Nichols DP
Ann Am Thorac Soc; 2014 Mar; 11(3):342-50. PubMed ID: 24476418
[TBL] [Abstract][Full Text] [Related]
28. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
Antoniu S
Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
[TBL] [Abstract][Full Text] [Related]
29. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
Pesaturo KA; Horton ER; Belliveau P
Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
[TBL] [Abstract][Full Text] [Related]
30. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
[TBL] [Abstract][Full Text] [Related]
31. Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany.
Naehrig S; Schulte-Hubbert B; Hafkemeyer S; Hammermann J; Dumke M; Sieber S; ; Naehrlich L
Pulm Pharmacol Ther; 2023 Jun; 80():102214. PubMed ID: 37003541
[TBL] [Abstract][Full Text] [Related]
32. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
33. Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis.
Van de Kerkhove C; Goeminne PC; Kicinski M; Nawrot TS; Lorent N; Van Bleyenbergh P; De Boeck K; Dupont LJ
J Cyst Fibros; 2016 Nov; 15(6):802-808. PubMed ID: 27720321
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
[TBL] [Abstract][Full Text] [Related]
36. Inhaled antibiotics for long-term therapy in cystic fibrosis.
Ryan G; Singh M; Dwan K
Cochrane Database Syst Rev; 2011 Mar; (3):CD001021. PubMed ID: 21412868
[TBL] [Abstract][Full Text] [Related]
37. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
38. New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.
Campbell CT; McCaleb R; Manasco KB
Ann Pharmacother; 2016 Feb; 50(2):133-40. PubMed ID: 26692274
[TBL] [Abstract][Full Text] [Related]
39. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
40. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Panguluri S; Gunda P; Debonnett L; Hamed K
Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
